Today, the U.S. Food and Drug Administration (FDA) approved a new recombinant growth hormone manufactured by the Canadian drug company, Cangene, and designed for subcutaneous injection. The brand name for Cangene’s injectable growth hormone is Accretropin. Accretropin has an identical amino acid sequence to natural human growth hormone produced in the pituitary. It was approved for treatment of children with short stature and Turner’s Syndrome (a chromosomal disorder in girls resulting in short stature and infertility). Cangene submitted the new drug application (NDA) to the FDA in July 2006.
Accretropin joins several other 191-amino acid sequence growth hormone brands currently approved by the FDA including Nutropin AQ, Saizen, Genotropin, Humatrope, Serostim, Zorbtive, Norditropin and Zomacton
More Steroid Articles from MESO-Rx:
- Pharmaceutical Company Studying Growth Hormone and IGF-1 Stack
- Growing Beyond What Nature Intended Part 1
- Sylvester Stallone Explains Therapeutic Benefits of Growth Hormone
- Scientists Hit Another Road Block in their Attempts to Detect Growth Hormone Use by Athletes
- Thyroid Hormone + Growth Hormone – If You Aren’t Using T4 with Your GH, You’re Not Doing It Right
